Stockreport

Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

Calithera Biosciences, Inc.  (CALA) 
Last calithera biosciences, inc. earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: calithera.com
PDF SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discoverin [Read more]